McDonald 2022 |
The provision of individualised deprescribing reports
supplied within 3 business days of patient admission, based on
evidence-based guidelines for safer prescribing in older adults, with
tapering instructions when indicated, generated by MedSafer software.
Gabapentinoids were listed as a “potentially inappropriate
medication”. |
925 participants of which 729 were identified to have
potentially been inappropriately prescribed |
Usual care (best-possible
medication history performed) |
Dose cessation or reduction, ADEs and
SAEs, QoL |
Short-term |
Kasper 2014
|
A 24-wk placebo- and lorazepam-controlled,
randomized, double-blind, multicentre trial. Period 1 contained a 6-week
fixed dose of either high dose pregabalin (450-600mg/day), low dose
pregabalin (150-300 mg/day), or lorazepam. Responders continued for
another 6 weeks. Then, in the double-blind period 2, 25% of patients
from each medication group were randomised to discontinue the active
medication by receiving a matching placebo.
|
206 participant per group underwent 12 weeks of high or low dose
pregabalin (Period 1), then randomised to:
Maintain low dose (n =112) versus placebo (n = 39)
OR
Maintain high dose (n = 121) versus placebo (n = 38)]
|
Placebo
|
Does cessation, ADEs, including ADWEs, SAEs, QoL
|
Intermediate-term
|
Chazot 2021a
|
Clinicians received GOTT (Gabapentinoids and Opioids Tapering Tool Box),
to improve confidence of clinicians and patients to self-manage pain
with safe prescribing. 10 Footsteps programme to achieve this goal was
developed to increase the motivation:
(a) for health care professionals to listen to patients,
(b) patients to understand their pain and engage with strategies that
help their long-term management,
(c) create communities that are sufficiently socially resilient to allow
that to happen (Ten Footsteps - Live Well With Pain).
|
Not reported
|
Nil
|
Reduction in prescribing rates
|
Intermediate-term
|
Collinson 2019a
|
Chart review of patients in May 2018
to determine baseline prescribing of gabapentinoids (n = 144 patients),
plus a review of prescription charts of a randomised sample (n = 30)
were accessed to ascertain whether indications were listed by the
British National Formulary. Airedale Clinical Commissioning Group
reported that 2% of patients registered at Haworth Medical Practice
were taking gabapentinoids. |
30 participants randomly chosen out of the
144 patients prescribed a gabapentinoid in May 2018 |
Nil |
Reduction in
prescribing rates |
Intermediate-term |